Spots Global Cancer Trial Database for CP-675,206 In Patients With Advanced Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CP-675,206 In Patients With Advanced Melanoma
Official Title: Phase 1 Open Label, Non-Randomized, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Immune Function Effects, And Efficacy Of Multiple Doses Of CP-675,206 In Patients With Advanced Melanoma, And Phase 2, Open Label, Randomized Study To Evaluate the Efficacy, Safety, Tolerability And Pharmacokinetics Of 2 Regimens Of CP-675,206 In Patients With Advanced Melanoma.
Study ID: NCT00086489
Conditions
Study Description
Brief Summary: The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Los Angeles, California, United States
Research Site, Tampa, Florida, United States
Research Site, Chicago, Illinois, United States
Research Site, Ann Arbor, Michigan, United States
Research Site, Ann Arbor, Michigan, United States
Research Site, Pittsburgh, Pennsylvania, United States
Research Site, Pittsburgh, Pennsylvania, United States
Research Site, Nashville, Tennessee, United States
Research Site, Houston, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
